Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd (CNTB): 1 pipeline candidate · 3 upcoming catalysts · ~9 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.1 months
D/E 0.41 · 0% dilution
Lead: Phase 2
1 candidate
3 upcoming, next in ~12d
2 buys · 0 sells (180d)
A transparent, data-derived signal for Connect Biopharma Holdings Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$131.0M
Cash
$46.0M
Quarterly Burn
$16.0M
Runway
9.1 mo
Revenue
$169K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| rademikibart | Phase 2 |
Upcoming Catalysts (3)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
36
Total value held
$18.4M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 1,585,392 | $4.2M |
| boothbay fund management, llc | 1,271,582 | $3.3M |
| 683 capital management, llc | 900,000 | $2.4M |
| adar1 capital management, llc | 742,400 | $1.9M |
| millennium management llc | 474,601 | $1.2M |
| knott david m jr | 387,835 | $1.0M |
| susquehanna international group, llp | 324,108 | $849K |
| propel bio management, llc | 209,493 | $554K |
| diadema partners lp | 200,690 | $526K |
| burkehill global management, lp | 150,000 | $360K |
Showing top 10 of 36 institutional holders of Connect Biopharma Holdings Ltd. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Connect Biopharma Holdings Ltd's pipeline?
Connect Biopharma Holdings Ltd (CNTB) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Connect Biopharma Holdings Ltd's lead drug candidate?
Connect Biopharma Holdings Ltd's most advanced tracked candidate is rademikibart (Phase 2) for acute exacerbations of COPD.
What is Connect Biopharma Holdings Ltd's next catalyst?
Connect Biopharma Holdings Ltd's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: rademikibart" — expected June 30, 2026.
What is Connect Biopharma Holdings Ltd's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Connect Biopharma Holdings Ltd has approximately 9.1 months of cash runway.
What is Connect Biopharma Holdings Ltd's market capitalization?
Connect Biopharma Holdings Ltd's market capitalization is approximately $131.0M.
Get the full picture on Connect Biopharma Holdings Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.